XJB-5-131 (C007B-433273)

XJB-5-131 is a mitochondria-targeted ROS and electron scavenger. XJB-5-131 is a bi-functional antioxidant that comprises a radical scavenger. XJB-5-131 is a synthetic antioxidant that targets mitochondria . XJB-5-131 is an effective ionizing irradiation protector and mitigator of cord blood mononuclear cells (CB MNCs) .In VitroXJB-5-131 also ameliorates hemorrhagic shock (HS)-induced activation of the pro-apoptotic enzymes, caspases 3 and 7, in ileal mucosa. XJB-5-131 reduces apoptosis and enhances cell survival in mouse embryonic cells in vitro. XJB-5-131 is a radiation protector for colony-forming unit-granulocyte macrophage (CFU-GM). XJB-5-131 is an effective mitigator when added after irradiation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Low density mononuclear cells (MNC) Concentration: 10 μM Incubation Time: Added to cells one hour before irradiation or immediately after irradiation Result: Was a protector when given before irradiation as shown by an increase in the D0 to 1.93±0.13 for CFU-GM with XJB-5-131.In VivoXJB-5-131 ameliorates peroxidation of the mitochondrial phospholipid, cardiolipin, in ileal mucosal samples from rats subjected to hemorrhagic shock (HS) . Intravenous treatment with XJB-5-131 (2 μmol/kg) significantly prolongs the survival of rats subjected to profound blood loss (33.5 mL/kg) despite administration of only a minimal volume of crystalloid solution (2.8 mL/kg) and the absence of blood transfusion . XJB-5-131 reduces oxidative damage to mitochondrial DNA, maintains mitochondrial DNA copy number, suppresses motor decline and weight loss, enhances neuronal survival, and improves mitochondrial function. XJB-5-131 significantly suppresses the disease phenotypes and improves mitochondrial function in a mouse model of Huntington’s disease (HD). XJB-5-131 (1 mg/kg; intraperitoneally injected; three times a week up to 57 weeks) suppresses decline of weight loss and motor function in a mouse model of HD. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male specific pathogen-free Sprague-Dawley rats, weighing 150 to 250 g Dosage: 2 μmol/kg Administration: Administered intravenously using a syringe pump Result: The rats treated with XJB-5-131 survived significantly longer (P < 0.01). Three of six survived for longer than 3 hours after completion of the hemorrhage protocol and one rat survived for the whole 6 hours postbleeding observation period. Animal Model: HD150KI miceDosage: 1 mg/kg Administration: Intraperitoneally injected; three times a week up to 57 weeks Result: Chronic treatment suppressed weight loss. Increased the average body mass by 22%.Form:Solid. Specification: ≥98.0% Molecular Formula: C53H81N7O9 Molecular Weight: 960.25 PubChem CID: 11693686 Isomeric SMILES: CC(C)C[C@@H](/C=C/[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=O)OCC3=CC=CC=C3)C(=O)NC4CC(N(C(C4)(C)C)[O])(C)C)NC(=O)OC(C)(C)C

UPC:

51132233

Condition:

New

Weight:

1.06 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

X650484-5mg

CAS:

866404-31-1

Product Size:

5mg